title: Inter-current and nosocomial infections among visceral leishmaniasis patients in Ethiopia: an observational study.
abstract: From July 1989 up to September 1997, a total of 247 non-HIV associated visceral leishmaniasis (VL) patients were treated on outpatient basis in rural clinics (195 patients) and hospitalised in the Northern-Omo Regional Hospital (18 patients) and in Addis Ababa referral hospitals (34 patients). Patients treated in the rural clinics and in the Regional hospital originated from the same endemic area and had comparable baseline characteristics. Overall rates of complications (inter-current/concurrent infectious or non-infectious diseases or deaths) in the three categories were 10.7, 38.9 and 61.6%, while case fatality rates were 2.5, 5.6 and 11.7%, respectively. Nosocomial bacterial infections occurred in 16.6% of patients treated in the Regional hospital and 32.3% of patients treated in Addis Ababa referral hospitals, and these infections accounted for 42.8 and 52.4% of the complications seen in the respective categories. Among VL patients originating from the same endemic place and with comparable baseline clinical data, patients treated hospitalised had significantly higher rates of complications than patients treated on outpatient basis (P<0.001). Patients who had complications during the course of VL therapy had significantly lower pre-treatment haemoglobin levels. Considering the extra cost of hospitalisation and risk of nosocomial infections and petavalent antimonial therapy being fairly safe, we recommend that VL patients, unless with serious complications, should preferably be treated on ambulatory basis with follow-up to monitor response and inter-current infections if any.
authors.affiliation: Institute of Pathobiology, Addis Ababa University, PO Box 1176, Addis Ababa, Ethiopia. nega_berhe@yahoo.com
authors.forename: N
authors.initials: N
authors.lastname: Berhe
authors.forename: A
authors.initials: A
authors.lastname: Hailu
authors.forename: Y
authors.initials: Y
authors.lastname: Abraham
authors.forename: Y
authors.initials: Y
authors.lastname: Tadesse
authors.forename: K
authors.initials: K
authors.lastname: Breivik
authors.forename: Y
authors.initials: Y
authors.lastname: Abebe
mesh_terms: D000293:Adolescent; D000328:Adult; D000553:Ambulatory Care; D000818:Animals; D000981:Antiprotozoal Agents / Q000627:therapeutic use; D002648:Child; D002675:Child, Preschool; D003428:Cross Infection / Q000453:epidemiology* / Q000469:parasitology; D005002:Ethiopia / Q000453:epidemiology; D005260:Female; D006760:Hospitalization; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D007893:Leishmania donovani; D007898:Leishmaniasis, Visceral / Q000150:complications / Q000188:drug therapy / Q000453:epidemiology*; D008297:Male; D008536:Meglumine / Q000627:therapeutic use; D000077485:Meglumine Antimoniate; D009942:Organometallic Compounds / Q000627:therapeutic use; D012424:Rural Population; D016896:Treatment Outcome; D014505:Urban Population
chemical_list: D000981:Antiprotozoal Agents; D009942:Organometallic Compounds; D008536:Meglumine; D000077485:Meglumine Antimoniate